These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. BonDurant LD; Ameka M; Naber MC; Markan KR; Idiga SO; Acevedo MR; Walsh SA; Ornitz DM; Potthoff MJ Cell Metab; 2017 Apr; 25(4):935-944.e4. PubMed ID: 28380381 [TBL] [Abstract][Full Text] [Related]
5. FGF21 requires βklotho to act in vivo. Adams AC; Cheng CC; Coskun T; Kharitonenkov A PLoS One; 2012; 7(11):e49977. PubMed ID: 23209629 [TBL] [Abstract][Full Text] [Related]
6. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Owen BM; Ding X; Morgan DA; Coate KC; Bookout AL; Rahmouni K; Kliewer SA; Mangelsdorf DJ Cell Metab; 2014 Oct; 20(4):670-7. PubMed ID: 25130400 [TBL] [Abstract][Full Text] [Related]
7. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. Kurosu H; Choi M; Ogawa Y; Dickson AS; Goetz R; Eliseenkova AV; Mohammadi M; Rosenblatt KP; Kliewer SA; Kuro-O M J Biol Chem; 2007 Sep; 282(37):26687-26695. PubMed ID: 17623664 [TBL] [Abstract][Full Text] [Related]
8. Physiology and Endocrinology Symposium: FGF21: Insights into mechanism of action from preclinical studies. Antonellis PJ; Kharitonenkov A; Adams AC J Anim Sci; 2014 Feb; 92(2):407-13. PubMed ID: 24398833 [TBL] [Abstract][Full Text] [Related]
9. FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity. Ye M; Lu W; Wang X; Wang C; Abbruzzese JL; Liang G; Li X; Luo Y Endocrinology; 2016 Dec; 157(12):4754-4769. PubMed ID: 27690692 [TBL] [Abstract][Full Text] [Related]
10. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Suzuki M; Uehara Y; Motomura-Matsuzaka K; Oki J; Koyama Y; Kimura M; Asada M; Komi-Kuramochi A; Oka S; Imamura T Mol Endocrinol; 2008 Apr; 22(4):1006-14. PubMed ID: 18187602 [TBL] [Abstract][Full Text] [Related]
11. Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex. Kolumam G; Chen MZ; Tong R; Zavala-Solorio J; Kates L; van Bruggen N; Ross J; Wyatt SK; Gandham VD; Carano RA; Dunshee DR; Wu AL; Haley B; Anderson K; Warming S; Rairdan XY; Lewin-Koh N; Zhang Y; Gutierrez J; Baruch A; Gelzleichter TR; Stevens D; Rajan S; Bainbridge TW; Vernes JM; Meng YG; Ziai J; Soriano RH; Brauer MJ; Chen Y; Stawicki S; Kim HS; Comps-Agrar L; Luis E; Spiess C; Wu Y; Ernst JA; McGuinness OP; Peterson AS; Sonoda J EBioMedicine; 2015 Jul; 2(7):730-43. PubMed ID: 26288846 [TBL] [Abstract][Full Text] [Related]
12. Levels of β-klotho determine the thermogenic responsiveness of adipose tissues: involvement of the autocrine action of FGF21. Moure R; Cairó M; Morón-Ros S; Quesada-López T; Campderrós L; Cereijo R; Hernáez A; Villarroya F; Giralt M Am J Physiol Endocrinol Metab; 2021 Apr; 320(4):E822-E834. PubMed ID: 33615874 [TBL] [Abstract][Full Text] [Related]
14. Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. Foltz IN; Hu S; King C; Wu X; Yang C; Wang W; Weiszmann J; Stevens J; Chen JS; Nuanmanee N; Gupte J; Komorowski R; Sekirov L; Hager T; Arora T; Ge H; Baribault H; Wang F; Sheng J; Karow M; Wang M; Luo Y; McKeehan W; Wang Z; Véniant MM; Li Y Sci Transl Med; 2012 Nov; 4(162):162ra153. PubMed ID: 23197570 [TBL] [Abstract][Full Text] [Related]
15. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317 [TBL] [Abstract][Full Text] [Related]
16. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects. Xu J; Stanislaus S; Chinookoswong N; Lau YY; Hager T; Patel J; Ge H; Weiszmann J; Lu SC; Graham M; Busby J; Hecht R; Li YS; Li Y; Lindberg R; Véniant MM Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1105-14. PubMed ID: 19706786 [TBL] [Abstract][Full Text] [Related]
17. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524 [TBL] [Abstract][Full Text] [Related]
18. FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. Lan T; Morgan DA; Rahmouni K; Sonoda J; Fu X; Burgess SC; Holland WL; Kliewer SA; Mangelsdorf DJ Cell Metab; 2017 Nov; 26(5):709-718.e3. PubMed ID: 28988823 [TBL] [Abstract][Full Text] [Related]
19. FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue. Markan KR; Naber MC; Small SM; Peltekian L; Kessler RL; Potthoff MJ Mol Metab; 2017 Jun; 6(6):602-610. PubMed ID: 28580290 [TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 21: a regulator of metabolic disease and health span. Xie T; Leung PS Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E292-E302. PubMed ID: 28559437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]